

REFERENCES

- Abraham, P. R. *et al.* (2015) 'Drug susceptibility profiles of Mycobacterium tuberculosis isolates from Gulbarga, South India', *Egyptian Journal of Chest Diseases and Tuberculosis*, 64(4), pp. 933–937.
- Adilistya, T. (2016) 'Manfaat Pemeriksaan Interferon-Gamma Release Assay untuk Diagnosis Tuberkulosis di Indonesia', *Cermin Dunia Kedokteran*, 43(7), pp. 545–550.
- Agyeman, A. A. and Ofori-Asenso, R. (2017) 'Tuberculosis—an overview', *Journal of Public Health and Emergency*, 1(3), pp. 7–7.
- Ahmad, S. *et al.* (2016) 'Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country', *PLoS ONE*, 11(4), pp. 1–16.
- Al Ubaidi, B. A. (2018) 'The Radiological Diagnosis of Pulmonary Tuberculosis (TB) in Primary Care', *Journal of Family Medicine and Disease Prevention*, 4 (1), pp.1-7.
- Aljeldah, M. M. (2020) 'Antibiotic sensitivity of Mycobacterium tuberculosis isolates; a retrospective study from a Saudi tertiary hospital', *Journal of Taibah University Medical Sciences*, 15(2), pp. 142–147.
- Asyary, A. *et al.* (2019) 'Predicting transmission of pulmonary tuberculosis in daerah istimewa Yogyakarta province, Indonesia', *Geospatial Health*, 14(1).
- Atashi, S., *et al.* (2017). 'Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran', *New Microbes and New Infections*, 19(1), pp.117-120.
- Cabibbe, A. M. *et al.* (2017) 'Genotypic and phenotypic M. tuberculosis resistance: Guiding clinicians to prescribe the correct regimens', *European Respiratory Journal*, 50(6), pp. 1–5.
- Chandrasekaran P. *et al.* (2018) 'Tuberculin skin test and QuantiFERON-Gold In Tube assay for diagnosis of latent TB infection among household contacts of pulmonary TB patients in high TB burden setting', *PLoS ONE*, 13 (8), pp. 1-16.

- Cruz, A.T., and Starke, J. R. (2010) 'Pediatric Tuberculosis', *Pediatrics in Review*, 31 (1), pp.13-26.
- Dinas Kesehatan D.I.Yogyakarta. (2016). Profil Kesehatan Provinsi Daerah Istimewa Yogyakarta Tahun 2016. *Dinas Kesehatan DIY*.
- Dinas Kesehatan D.I.Yogyakarta. (2017). Profil Kesehatan Provinsi Daerah Istimewa Yogyakarta Tahun 2017. *Dinas Kesehatan DIY*.
- Dinas Kesehatan D.I.Yogyakarta. (2019). Profil Kesehatan Provinsi Daerah Istimewa Yogyakarta Tahun 2019. *Dinas Kesehatan DIY*.
- Dookie, N., Sturm, A. W. and Moodley, P. (2016) 'Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa', *BMC Infectious Diseases*, 16(1), pp. 1–8.
- Gilpin, C., Korobitsyn, A. and Weyer, K. (2016) 'Current tools available for the diagnosis of drug-resistant tuberculosis', *Therapeutic Advances in Infectious Disease*, 3(6), pp. 145–151.
- Horvat, R.T. (2015) 'Gamma Interferon Assays Used in the Diagnosis of Tuberculosis', *Clinical and Vaccine Immunology*, 22 (8), pp.845-849.
- Humaira. (2013) 'Faktor-Faktor Yang Berhubungan Dengan Perilaku Pasien Tuberkulosis Paru Dalam Pencegahan Penularan Tuberkulosis Di Puskesmas Tangerang Selatan Tahun 2013', *UIN Syarif Hidayatullah Jakarta*, pp. 1-26.
- Huo, F. *et al.* (2020) 'Interpretation of discordant rifampicin susceptibility test results obtained using GeneXpert vs phenotypic drug susceptibility testing', *Open Forum Infectious Diseases*, 7(8), pp. 1–7.
- Iacobino, A., Fattorini, L. and Giannoni, F. (2020) 'Drug-resistant tuberculosis 2020: Where we stand', *Applied Sciences (Switzerland)*, 10(6), pp. 1–17.
- Jahja T. W. (2018) 'Korelasi Kadar Serum Ifn- Γ , Ekspresi Dan Fungsi Reseptor Ifn- Γ , Dengan Kejadian Tuberkulosis Paru', *Indonesian Journal of Applied Science*, 3 (3), pp.1-4.
- Jeong, Y. J., Lee, K. S. and Yim, J.-J. (2017) 'The diagnosis of pulmonary tuberculosis: a

Korean perspective', *Precision and Future Medicine*, 1(2), pp. 77–87.

Jo K. W. *et al.* (2017) 'Analysis of discrepant results between the Genotype®MTBDRplus assay and an antimicrobial drug susceptibility test for isoniazid-resistant tuberculosis', *Respir Med*, 122 (1), pp. 12-7.

Kang, J. Y. *et al.* (2019) 'Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients', *Journal of Thoracic Disease*, 11(2), pp. 400–409.

Kementerian Kesehatan Indonesia. (2018). Penanggulangan Tuberkulosis. Indonesia: Kementerian Kesehatan Indonesia.

Kerubo, G. *et al.* (2016) 'Drug susceptibility profiles of pulmonary Mycobacterium tuberculosis isolates from patients in informal urban settlements in Nairobi, Kenya', *BMC Infectious Diseases*, 16(1), pp. 1–7.

Khan, Z. A., Siddiqui, M. F. and Park, SK. (2019) 'Current and Emerging Methods of Antibiotic Susceptibility Testing', *MDPI (Multidisciplinary Digital Publishing Institute) Journal Applied Science*, 9(2), pp. 1-17.

Kim, S. J. (2005) 'Drug-susceptibility testing in tuberculosis: methods and reliability of results', *European Respiratory Journal*, 25(3), pp. 564–569.

Kowalak JP, Welsh W, Mayer B. (2011). Professional Guide to Patophysiology. 3rd Edition. Jakarta: EGC.

Kusumawati, R. L. *et al.* (2018) 'Predictors of multidrug resistance among pulmonary tuberculosis patients in a tertiary hospital in North Sumatera, Indonesia', *Bali Medical Journal*, 7(1), p. 68.

Lawn, S. D., & Nicol, M. P. (2011) 'Xpert®MTB/RIF assay: Development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance'. *Future Microbiology*, 6(9), pp.1067-1082.

- Lumb, R., Van Deun, A., Bastian, A. and Fitz-Gerald, M. (2013). Laboratory Diagnosis of Tuberculosis Sputum Microscopy, Global Laboratory Initiative. Adelaide: SA Pathology.
- Migliori, G. B. *et al.* (2008) 'Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges', *Canadian Journal of Infectious Diseases and Medical Microbiology*, 19(2), pp. 169–172.
- Migliori, G. *et al.* (2020) 'MDR / XDR-TB management of patients and contacts : Challenges facing the new decade', *International Journal of Infectious Diseases*, 9 (2), pp. s15-s25.
- Narasimhan, P. *et al.* (2013) 'Risk Factors for Tuberculosis'. *Hindawi Publishing Corporation Pulmonary Medicine*, 1, pp.1-11.
- Nayak, S. and Acharjya, B. (2012) 'Mantoux test and its interpretation', *Indian Dermatology Online Journal*, 3(1), p. 1-2.
- Nguyen, T. N. A. *et al.* (2019) 'Molecular diagnosis of drug-resistant tuberculosis; A literature review', *Frontiers in Microbiology*, 10(MAR), pp. 1–12.
- Pahal P. and Sharma, S. (2020) 'PPD Skin Test (Tuberculosis Skin Test)', *StatPearls Publishing*, 2, pp. 1.
- Pawar, S. S., Shah, S. R. and Udgaonkar, U. S. (2016) 'Comparison of Conventional Lowenstein Jensen Medium and Middlebrook Biphasic Medium for isolation of Mycobacterium Tuberculosis', *International Journal of Contemporary Medical Research*, 3(6), pp. 1583–1586.
- Peraturan Walikota Yogyakarta. (2017). *Peraturan Walikota Yogyakarta tentang Rencana Aksi Daerah Penanggulangan Tuberkulosis*. Available at: [https://hukum.jogjakota.go.id/data/Perwal No 102 Tahun 2017 ttg Rencana Aksi Daerah Penanggulangan Tuberkulosis Tahun 2017-2021.pdf](https://hukum.jogjakota.go.id/data/Perwal%20No%20102%20Tahun%202017%20ttg%20Rencana%20Aksi%20Daerah%20Penanggulangan%20Tuberkulosis%20Tahun%202017-2021.pdf)
- Puspasari, N. (2014) 'Karakteristik Pasien Tuberkulosis Yang Memperoleh Pengobatan Kategori 2 Di Provinsi Kalimantan Barat Tahun 2009 – 2012', *Universitas Tanjung Harapan*, 1(1), pp. 13-23.

- Quamila, A. (2018). *Efek Samping Obat TBC yang Perlu Anda Waspadai*. Available at: <https://helohehat.com/pusat-kesehatan/tuberculosis-tbc/efek-samping-obattbc/> [Accessed: 18 May 2020].
- Ryu, Y. J. (2015) 'Diagnosis of Pulmonary Tuberculosis: Recent Advances and Diagnostic Algorithms', *Tuberculosis and Respiratory Diseases*, 78 (2), pp.64-71.
- Setiati S. (2014). *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Interna Publishing.
- Seki, M. *et al.* (2018) 'Recent advances in tuberculosis diagnostics in resource-limited settings', *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology*, 37 (8), pp.1405–1410.
- Siddiqi, S. *et al.* (2012) 'Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the bactec MGIT 960 system: A multicenter study', *Journal of Clinical Microbiology*, 50(2), pp. 435–440.
- Smith, I. (2003). 'Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence', *Clinical Microbiology Reviews*, 16 (3), pp. 463-496.
- Smith, T., Wolff, K. A., & Nguyen, L. (2012) 'Molecular Biology of Drug Resistance in Mycobacterium tuberculosis', *Current Topics in Microbiology and Immunology*, 374, pp. 53-80.
- Sotgiu, G., Centis, R., Dambrosio, L., & Migliori, G. B. (2015) 'Tuberculosis Treatment and Drug Regimens', *Cold Spring Harbor Perspectives in Medicine*, 5 (5), pp. 1-12.
- Sudha, S. (2016) 'Tuberculosis diagnosis - An overview to the conventional diagnostic methodology and need for nanodiagnosis', *International Journal of Medical Engineering and Informatics*, 8(1), pp. 27–40.
- Sulis, G. *et al.* (2014) 'Tuberculosis: epidemiology and control', *Mediterranean Journal Of Hematology and Infectious Diseases*, 6 (1), pp. 1-8.
- The Union. (2018). *Field Guide for The management of Drug-Resistant Tuberculosis*. France: International Union against Tuberculosis and Lung Disease (The Union).

Theron, G. *et al.* (2018) ‘False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes’, *Journal of Clinical Microbiology*, 56(3), pp. 1-9.

Treatment Action Group. (2017). *An Activist’s Guide to Tuberculosis Diagnostic Tools*. New York: Treatment Action Group.

World Health Organization. (2008) ‘Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs’, *World Health Organization*, pp. 1–20.

World Health Organization. 2010. *Treatment Of Tuberculosis Guidelines*. [online] Available at: https://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf?sequence=1 [Accessed 28 December 2020].

World Health Organization. 2014. *Xpert MTB/RIF Implementation Manual Technical And Operational ‘How-To’: Practical Considerations*. [online] Available at: https://apps.who.int/iris/bitstream/handle/10665/112469/9789241506700_eng.pdf?sequence=1 [Accessed 28 December 2020].

World Health Organization (2016) ‘The use of molecular line probe assays for the detection of mutations associated with resistance to fluoroquinolones (FQs) and second-line injectable drugs (SLIDs). Policy guidance.’, *World Health Organisation*. Available at: <https://www.who.int/tb/WHOPolicyStatementSLLPA.pdf>.

World Health Organization. 2018. *Global Tuberculosis Report 2018*. [online] Available at: https://www.who.int/tb/publications/global_report/gtbr2018_main_text_28Feb2019.pdf [Accessed 28 December 2020].

World Health Organization. 2018. *Technical Manual For Drug Susceptibility Testing Of Medicines Used In The Treatment Of Tuberculosis*. [online] Available at: <https://apps.who.int/iris/bitstream/handle/10665/275469/9789241514842-eng.pdf?ua=1> [Accessed 28 December 2020].

World Health Organization. 2019. *Global Tuberculosis Report 2019*. [online] Available at: <https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf> [Accessed 28 December 2020].

World Health Organization. 2020. *Tuberculosis (TB)*. [online] Available at: <<https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis>> [Accessed 24 June 2020].

World Health Organization. 2020 *Definitions and reporting framework for tuberculosis - 2013 revision (updated Dec 2014 and Jan 2020) (WHO/ HTM/TB/2013.2)*, *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23611033>.

Widoyono. (2011). *Penyakit Tropis Epidemiologi, Penularan, Pencegahan dan Pemberantasannya*. 2nd Edition. Jakarta: Erlangga.

Zhang, T. *et al.* (2016) 'Direct tuberculosis drug susceptibility testing: time-saving and cost-effective in detecting MDR-TB', *The International Journal of Tuberculosis and Lung Disease*, 20 (3), pp.1-7.

Zulkoni Akhsin. (2010). *Parasitologi*. Yogyakarta: Nuha Medika.